Cambrex to Exhibit at CPhI Worldwide 2011
Rick Offerman, Ph.D., Associate Director, Marketing Services
Stephanie Harrison, Marketing Manager
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, 'Cambrex") will be exhibiting at CPhI Worldwide 2011, October 25-27 in Frankfurt, Germany, at the Messe Frankfurt. Attendees are encouraged to visit Cambrex’s booth to learn more about the Company’s wide range of custom development and manufacturing services as well as several innovative technologies for the pharmaceutical industry. Cambrex manufactures over 120 generic and proprietary Active Pharmaceutical Ingredients (APIs) and advanced intermediate products and sells to most major innovator and generic pharma companies.
CPhI is the world’s largest pharma event and Cambrex will showcase its global development and manufacturing capabilities including specialized offerings related to DEA controlled substances, High Potency APIs (HPAPIs) and highly energetic chemistries. In addition, Cambrex will highlight its biotransformation capabilities, drug delivery technologies, finished dosage form capabilities and feature its CPhI 2009 Silver Innovation Award winning Continuous-Flow Microwave-Assisted Organic Synthesis technology.
Cambrex will have representatives from its manufacturing sites in Milan, Italy, Charles City, Iowa, Karlskoga, Sweden, Hyderabad, India, and research facilities in Wiesbaden, Germany, and Tallinn, Estonia on site for discussions with customers on generic and proprietary products, custom development and finished dosage form development and manufacturing.
Cambrex will be exhibiting in Hall 3.0, Booth 30D39 in the API product zone.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.